Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug crawled date : 2021 - 12 - 20 save search
CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
CTMX | $1.67 -3.47% -3.59% 510K
|
Health Technology
|
| O: -21.71%
H: 0.29%
C: -23.37%
cx-2029 phase 2 ongoing expansion drug therapeutics results antibody
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market Report 2021-2026: Competitor Landscape, Opportunity Assessment, Approved Drugs, Drugs Patent, Price and Sales insights
Published: 2021-12-20 (Crawled : 19:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.18%
H: 0.02%
C: -0.51%
sales drug patent cel therapy t-cell
Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia
Published: 2021-12-20 (Crawled : 15:00) - biospace.com/
EDIT | $5.5 -0.9% -0.91% 2.3M
|
Health Technology
|
| O: 4.96%
H: 6.56%
C: 4.21%
edit-301 new drug treatment fda clearance transfusion application drug fda clearance
PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
PTE | $0.241 -0.82% -6.68% 0
|
Consumer Durables
|
| O: 2.56%
H: 8.75%
C: 8.7%
skinte clinical hold new drug fda application drug skin pons submission response
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors
Published: 2021-12-20 (Crawled : 14:00) - biospace.com/
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: 7.29%
H: 8.01%
C: 7.4%
new drug fda clearance solid tumors application car-t drug therapeutics fda clearance
Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs
Published: 2021-12-20 (Crawled : 14:00) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 2.8%
H: 6.36%
C: 4.55%
health drug therapeutics disease orphan drug rare
LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE
Published: 2021-12-20 (Crawled : 12:30) - biospace.com/
LCI | $0.6855 0.0% 19K
|
Health Technology
|
| O: -2.23%
H: 1.56%
C: -2.86%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.59%
H: 0.18%
C: -0.2%
new drug application drug insulin submission biosimilar glargine
Global Bioresorbable Polymers Market Report 2021: Growing Demand in Biocompatible Medical Devices ^& Drug Delivery Application - Forecast to 2026
Published: 2021-12-20 (Crawled : 12:00) - prnewswire.com
ASH | $95.99 0.52% 0.0% 410K
|
Process Industries
|
| O: -0.74%
H: 0.58%
C: 0.47%
ema application drug device liver growing drug delivery
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.